Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-JH12 is a novel radiopharmaceutical designed for positron emission tomography (PET) imaging. It specifically targets the C-X-C motif chemokine receptor 4 (CXCR4), which is highly expressed in various malignant tumors. By binding to CXCR4, 68Ga-JH12 enables non-invasive visualization of tumors with high CXCR4 expression, supporting cancer diagnosis and potentially patient stratification for targeted therapies. Preclinical studies have demonstrated its high stability, tumor-specific accumulation, strong binding affinity, safety, and selectivity. The agent is currently being evaluated in phase 1 clinical trials to assess its safety profile, biodistribution, and radiation dosimetry in patients with different types of solid tumors[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 68Ga-JH12.